LOW-VOLUME · SEX-BALANCED

tazarotene Side Effects

tazarotene (also sold as Tazorac) is a LOW-VOLUME FAERS extract #486 of 524 by FAERS report count. Still opens on SEX-BALANCED: 69% of sex-coded reports are female (681 F / 306 M).

Data updated 2026-05-15

1,132
FAERS reports

Thinner FAERS book - still a temporal association ledger, not proof of cause. Methodology.

tazarotene reporting skew - 69% of sex-coded reports are female (681 F / 306 M). Volume band LOW-VOLUME #486 of 524 by FAERS report count; caseload SIGNAL.

Thinner FAERS extract for tazarotene (Tazorac) (1,132 reports #486 of 524 by FAERS report count). 69% of sex-coded reports are female (681 F / 306 M). Sparse books still carry named reaction rows when present; not medical advice.

Counts from the openFDA FAERS extract (2004–2025). Stamps SIGNAL · DEATH-MARKED · HOSP-MID · SEX-BALANCED.

ERYTHEMA leads 82 of 1,132 reports

ERYTHEMA
82
SKIN EXFOLIATION
74
PAIN
64
PRURITUS
62
RASH
62
HEADACHE
55
APPLICATION SITE ERYTHEMA
45
ACNE
42
PSORIASIS
40
APPLICATION SITE PAIN
38
DRY SKIN
38
DIARRHOEA
32
FATIGUE
32
NAUSEA
32
PREGNANCY
32
BURNING SENSATION
31
SKIN IRRITATION
30
ARTHRALGIA
28

Who reports · age peak 18-44 (SEX-BALANCED)

Sex coding · SEX-BALANCED

Female 681 (69%)
Male 306 (31%)
Unknown 6

Age peak 18-44 (227 reports)

0-17 86 (15%)
18-44 227 (39%)
45-64 187 (32%)
65-74 44 (8%)
75+ 35 (6%)

FAERS filings rising toward 2025

2004 2025

Reactions in Death Reports

Death appears on 15 reports (1.3% - MARKED). Reactions below co-occur in those rows only.

Reaction Reports
DEATH 6
COVID-19 4
ILLNESS 4
IMMUNOSUPPRESSION 4
LUNG DISORDER 4
PNEUMOCYSTIS JIROVECII INFECTION 4
SKIN INFECTION 4
DRUG EXPOSURE DURING PREGNANCY 2
PREGNANCY 2
ABORTION SPONTANEOUS 1
ACUTE RESPIRATORY FAILURE 1
AFFECT LABILITY 1
AMMONIA INCREASED 1
ANENCEPHALY 1
ASTHENIA 1
BLOOD CHOLESTEROL INCREASED 1
BLOOD TRIGLYCERIDES INCREASED 1
CAESAREAN SECTION 1
CHRONIC HEPATIC FAILURE 1

Reactions in Hospitalization Reports

Hospitalization mid-share (159, 14.0%). Co-reported reactions:

Reaction Reports
DIARRHOEA 14
PAIN 14
ANXIETY 12
INFLAMMATORY BOWEL DISEASE 11
PULMONARY EMBOLISM 11
EMOTIONAL DISTRESS 10
INJURY 10
HEADACHE 9
HYPERTRANSAMINASAEMIA 9
COLITIS ULCERATIVE 8
DYSPNOEA 8
FATIGUE 8
PNEUMONIA 8
VOMITING 8
ABDOMINAL PAIN 7
ANAL HAEMORRHAGE 7
DEEP VEIN THROMBOSIS 7
DRUG EXPOSURE DURING PREGNANCY 7
DRY SKIN 7
How to read tazarotene FAERS figures (SIGNAL · DEATH-MARKED · HOSP-MID)

FAERS holds 1,132 voluntary reports linked to tazarotene (Tazorac), 2004-2025. Death is listed on 15 (1.3%). Hospitalization appears on 159 (14.0%). Top co-reported indication: Product Used For Unknown Indication.

Sparse extract - named reactions and SEX-BALANCED skew still differ by drug; not a complete safety profile.

Read with tazarotene

Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-MID stamps.